Roche signed on as the first partner for Dualitas Therapeutics’ Dualscreen bispecific discovery engine, committing to screen more than 300,000 bispecific antibody combinations. Dualitas will receive $36.5 million upfront, with additional research, development, and commercial milestones and tiered royalties up to $1 billion, targeting immunology and inflammation applications.